哌拉西林/他唑巴坦治疗细菌性感染在儿科临床疗效和评价  

Piperacillin/tazobactam against Bacterial Infections in Pediatrics: Evaluation of Clinical Efficacy and Safety

作　　者：宓越群[1] 鲍一笑[1] 稽若旭[1] 朱敏皓[1] 姚渭清[1] 

机构地区：[1]上海第二医科大学附属新华医院上海儿童医学中心,上海200092

出　　处：《中华医院感染学杂志》2005年第5期580-582,共3页Chinese Journal of Nosocomiology

摘　　要：目的　评价哌拉西林/他唑巴坦(TZP)在儿科治疗细菌性感染的临床疗效和安全性。方法　以64 例中重度细菌性患儿为试验对象,随机分入试验组(32例,哌拉西林/他唑巴坦)和对照组(32 例,阿莫西林/克拉维酸),进行治疗和观察。结果　试验组的临床有效率、对各种致病菌的有效率和清除率分别为93. 6%、92. 1%和86.3%;对照组相应分别为68. 7%、60. 2%和53. 4%,两组参数差异均有显著性;两组不良反应发生率均为6.1%。结论　哌拉西林/他唑巴坦抗菌疗效明显优于阿莫西林/克拉维酸,且安全性高,耐受性好,对儿科的中重度细菌感染,尤其是产酶菌的感染,有较高临床应用价值。OBJECTIVE To evaluate the clinical efficacy and safety of piperacillin/tazobactam (P/T) against bacterial infections in pediatrics. METHODS Sixty four patients with moderate or severe bacterial infections were enrolled in a randomized controlled clinical trial, 32 in trial group, 32 in control one, then treated and observed. RESULTS The clinical efficacy rates, the drug susceptibility rates of the bacteria isolated and the bacterial clearance rates were 96.3%, 92.1% and 86.3%, respectively in trial group, vs 68.7%, 60.2% and 53.4%, respectively in control one.The difference between the two groups was statistically significant. The adverse drug reactions of the two groups were both 6.1%. CONCLUSIONS P/T is of an extensive spectrum, high efficacy and safety in the treatment of moderate to severe bacterial infections.

关 键 词：哌拉西林/他唑巴坦 阿莫西林/克拉维酸 评价 安全性 临床疗效 

分 类 号：R969.3[医药卫生—药理学]